Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated computational and experimental workflows, leaving a persistent gap between primary screening hits and lead series.

Dr Greg Makara will review BioDuro's integrated FBDD platform, which directly addresses these challenges through a rationally designed fragment library built with ChemPass' proprietary knowledge-trained technology, Surface Plasmon Resonance (SPR)-driven hit identification, and a computational expansion engine that rapidly translates confirmed hits into focused compound collections for experimental confirmation.

Dr Shuo Gu will demonstrate this workflow on the MyD88 Toll-Interleukin receptor (TIR) domain, a high-value yet difficult-to-drug target in innate immunity implicated in inflammatory and autoimmune diseases. Long considered undruggable due to the challenging nature of its protein-protein interaction (PPI) interface, MyD88 serves as a representative example of how BioDuro’s FBDD platform can tackle hard-to-drug PPI targets across diverse therapeutic areas.

Join us to see this integrated FBDD platform in action!

What you will learn:

• A novel integrated platform for fragment-based screening and library expansion that accelerates the early stages of drug discovery
• Hit-based virtual library design and docking for efficient hit-to-lead optimisation
• A combined experimental and computational workflow that enables rapid hit identification for difficult-to-drug targets